PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract

  • Authors:
    • Michiko Akiyama
    • Yoko Matsuda
    • Tomio Arai
    • Hidehisa Saeki
  • View Affiliations

  • Published online on: January 21, 2020     https://doi.org/10.3892/ol.2020.11325
  • Pages: 2481-2488
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastrointestinal melanoma (GM) is a rare but aggressive type of malignant melanoma arising in the gastrointestinal tract. An anti‑programmed cell death protein 1 (PD‑1) antibody markedly improves prognosis in patients with melanoma. However, little is known regarding the expression of immune‑oncology biomarkers in GM compared with skin melanoma (SM), especially in the Asian population. the present study examined clinicopathological characteristics, PD‑L1 and HLA expression, and immune‑oncology marker expression in 10 cases of GM and 31 cases of SM. Patients with GM exhibited significantly higher incidences of lymph node and distant metastases than patients with SM (P=0.0448 and P=0.0247, respectively). The infiltration of CD8+ lymphocytes was significantly higher in GM than in SM (P=0.0231). The infiltration of PD‑1+ lymphocytes was higher in GM than in SM, but the difference was not significant (P=0.0975). PD‑L1‑positive melanoma exhibited a higher proportion of BRAFV600E‑positive melanoma than PD‑L1‑negative melanoma (P=0.0317; 39.4 and 0%, respectively). PD‑L1‑positive melanoma exhibited significantly higher rates of CD8+ and FOXp3+ lymphocyte infiltration than PD‑L1‑negative melanoma (P=0.0221 and P=0.0463, respectively). By contrast, PD‑1+ lymphocytes did not differ between PD‑L1‑positive and ‑negative cases. Furthermore, HLA‑positive melanoma exhibited higher proportions of PD‑1 (P=0.0101; 53.7 and 15.4%) and CD8 than HLA‑negative melanoma (P=0.0818; 66.7 and 38.2%). These results provided useful information regarding tumor immunity in GM and SM and may contribute to the development of treatment strategies for GM.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Akiyama, M., Matsuda, Y., Arai, T., & Saeki, H. (2020). PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract. Oncology Letters, 19, 2481-2488. https://doi.org/10.3892/ol.2020.11325
MLA
Akiyama, M., Matsuda, Y., Arai, T., Saeki, H."PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract". Oncology Letters 19.3 (2020): 2481-2488.
Chicago
Akiyama, M., Matsuda, Y., Arai, T., Saeki, H."PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract". Oncology Letters 19, no. 3 (2020): 2481-2488. https://doi.org/10.3892/ol.2020.11325